MedicalDevice Licensing.com
Pharmalicensing.com
Latest: Watch here for details of new products and services.
RSS Feeds
Advanced search

Login  Register

About Us
Pharmalicensing - Partnering solutions for the life sciences
 
Our Products
Overview
Partnering Search
Company Profiling
Deal Negotiation
PL Intelligence
Reports
Comparison
 
PL Intelligence
Overview
Industry news
Deals review
Press releases
Articles
 
Case Studies
See what others think about our service
 
Newsletter
Partnering update
Key reports
Subscribe
 
Quick Links
Profile now
Register now
Profiled companies
Featured events
Industry news
PR Newswire
Jobs
 
Contact Pharmalicensing
Send an email
Call us: +44 1904 520460
Request a callback
 
RSS Feeds
Keep up to date

Pharmalicensing
is a division of
UTEK Europe Ltd
UTEK Corporation
Out-licensing

Animal Technology Institute Taiwan (ATIT): A platform for the expression and production of multiple recombinant proteins in the milk of transgenic non-human mammals

BiotechEast Co., Ltd. (Technology Partner)
Technology regarding new methods to efficiently and cost-effectively produce recombinant proteins from the milk of genetically-modified farm animals, applying methodologies of genetic engineering and transgenesis to pharmaceutical manufacturing.

Full description

A platform has been developed to efficiently and cost-effectively produce recombinant proteins from the milk of genetically-modified farm animals, applying the methods of genetic engineering and transgenesis to pharmaceutical manufacturing.

ATIT-IX, a 55 kDa protein, is expressed in the milk of transgenic sows at 250 μg/mL. After lactation, ATIT-IX is purified from sow milk to homogeneity via anion and affinity chromatographic procedures, and the physical and chemical properties of ATIT-IX have been evaluated.

The platform uses manufacturing processes that are well-managed and carefully scrutinized in terms of quality control, quality assurance and production efficiency.

Currently, biological activity of ATIT-IX at higher levels than other commercial products has been demonstrated.

Bio-safety issues are always an important consideration in the production of biopharmaceutical proteins. Adventitious agents must be considered when dealing with biological products from transgenic animals. For this platform, bio-safety tests (endotoxin and virus) have been used to establish quality control for all the manufacturing processes; including those involved in milk production, milk collection, protein isolation and purification. Model viruses detection (porcine parvovirus and pseudorabies virus) and pyrogen tests were established to assess the safety of therapeutic proteins derived from swine in this platform.

Development status

Preclinical

Patent information

US and Taiwan patents of ATIT-IX production issued.

Type of business relationship sought

Patent licensing, technology transfer, partnering.

Clients in focus...

Get the Flash Player to see this rotator.

Partnering and licensing intelligence in life sciences industry
Press releases: Pharmalicensing current industry press releases.

© Copyright 1995-2009 Pharmalicensing, a division of UTEK Europe Ltd UTEK Corporation All rights reserved. Terms and Conditions | Contact us